Fundraising Fox

Protego Biopharma

San Diego, US · Delaware corporation · 28 employees on LinkedIn · 8 known investors

BiotechHealthtech

Founders & leadership

BJBrent J. Warner
Brent J. WarnerinChief Executive Officer, Board Member
XJ
XIN JIANGinCo-founder & VP Biology2021–2024
HM
HANK MICHAEL PETRASSINamed on SEC filing
JK
JEFFERY KELLYNamed on SEC filing

Board

TL
TIM LOHOFFBoard director
EH
Edward HurwitzBoard director
JN
JANWILLEM NAESENSBoard director
SB
SAOUSSEN BEN HALIMABoard director
LB
LAURA BRASSBoard director
SC
SHELLEY CHUBoard director
RL
Richard LabaudiniereChairman of the Board of Directors
HK
HELEN KIMBoard director

Investors · 8

Digitalis Venturesreported · 2 sourcesNew York · $100K – $10M
Droia Venturesreported · 2 sourcesLeuven · $540K
ForbionreportedNaarden
Lightspeed Venture Partnersreported · 2 sourcesMenlo Park · $1.7M – $87M
MPM BioImpactreported · 2 sourcesBoston · $1M – $15M
Novartis Venture Fundreported · 2 sourcesBasel · $5M – $25M
Vida Venturesreported · 2 sourcesLos Angeles
YK Bioventuresreported · 2 sourcesBurlingame

Reported raises · per SEC filings

Form D private placements

$85M disclosed across 3 rounds · 2019–2025

▶$32.9MraisedDec 2025 · 18 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • TIM LOHOFFDirector
  • EDWARD HURWITZDirector
  • HANK MICHAEL PETRASSIExecutive Officer
  • JANWILLEM NAESENSDirector
  • SAOUSSEN BEN HALIMADirector
  • LAURA BRASSDirector
  • JEFFERY KELLYDirector
  • Brent J. WarnerExecutive Officer, Director
  • SHELLEY CHUDirector
  • HELEN KIMDirector
Offering amount
$130.4M
Amount sold
$32.9M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$51MraisedOct 2021 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard LabaudiniereExecutive Officer, Director
  • Jeffrey KellyDirector
  • Edward HurwitzDirector
  • Shelley ChuDirector
  • Helen KimDirector
Offering amount
$51M
Amount sold
$51M
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedDec 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • XIN JIANGExecutive Officer
  • Edward HurwitzDirector
  • Jeffery W KellyPromoter
  • Richard LabaudiniereDirector
Offering amount
$1M
Amount sold
$1M
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
04, 06b, 4a5
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Biotech Funding 2025 Tracker: Follow the Latest Raises, Rounds and R&D Momentum - Xtalksxtalks.com · Jan 2026With $130M, Protego pushes forward a new type of amyloidosis drug | BioPharma Divebiopharmadive.com · Dec 2025Protego plans pivotal trial for AL amyloidosis prospect with $130M series Bfiercebiotech.com · Dec 2025Protego Raises $130 Million to Fund AL Amyloidosis Pivotal Study - Global Genesglobalgenes.org · Dec 2025Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Studyprnewswire.com · Dec 2025Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseasesglobenewswire.com · Nov 2021

Frequently asked questions

Who are Protego Biopharma's investors?
Protego Biopharma's investors include Digitalis Ventures, Droia Ventures, Forbion, Lightspeed Venture Partners, MPM BioImpact, Novartis Venture Fund, Vida Ventures, YK Bioventures.
How much funding has Protego Biopharma raised?
Protego Biopharma has disclosed $85M raised across 3 rounds.
Where is Protego Biopharma headquartered?
Protego Biopharma is headquartered in San Diego, US.